These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Santra A; Kumar R; Sharma P; Bal C; Kumar A; Julka PK; Malhotra A Eur J Radiol; 2012 Mar; 81(3):508-13. PubMed ID: 21353420 [TBL] [Abstract][Full Text] [Related]
6. ¹⁸F-FDG PET/CT and contrast enhanced CT in differential diagnosis between leiomyoma and gastrointestinal stromal tumor. Hirose Y; Kaida H; Kawahara A; Kurata S; Ishibashi M; Abe T Hell J Nucl Med; 2015; 18(3):257-60. PubMed ID: 26574696 [TBL] [Abstract][Full Text] [Related]
7. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT. Vogt FM; Antoch G; Veit P; Freudenberg LS; Blechschmid N; Diersch O; Bockisch A; Barkhausen J; Kuehl H J Nucl Med; 2007 Nov; 48(11):1836-44. PubMed ID: 17942811 [TBL] [Abstract][Full Text] [Related]
8. Missed causative tumors in diagnosing tumor-induced osteomalacia with (18)F-FDG PET/CT: a potential pitfall of standard-field imaging. Kaneuchi Y; Hakozaki M; Yamada H; Hasegawa O; Tajino T; Konno S Hell J Nucl Med; 2016; 19(1):46-8. PubMed ID: 26929940 [TBL] [Abstract][Full Text] [Related]
9. Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer. Dalah E; Moraru I; Paulson E; Erickson B; Li XA Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):633-40. PubMed ID: 24755533 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms. Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148 [TBL] [Abstract][Full Text] [Related]
11. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909 [TBL] [Abstract][Full Text] [Related]
12. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses. Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584 [TBL] [Abstract][Full Text] [Related]
13. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803 [TBL] [Abstract][Full Text] [Related]
14. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI. Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380 [TBL] [Abstract][Full Text] [Related]
15. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study. Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771 [TBL] [Abstract][Full Text] [Related]
16. Value of retrospective image fusion of ¹⁸F-FDG PET and MRI for preoperative staging of head and neck cancer: comparison with PET/CT and contrast-enhanced neck MRI. Kanda T; Kitajima K; Suenaga Y; Konishi J; Sasaki R; Morimoto K; Saito M; Otsuki N; Nibu K; Sugimura K Eur J Radiol; 2013 Nov; 82(11):2005-10. PubMed ID: 23891295 [TBL] [Abstract][Full Text] [Related]
17. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Zhang X; Wu F; Han P Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754 [TBL] [Abstract][Full Text] [Related]
18. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383 [TBL] [Abstract][Full Text] [Related]
19. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
20. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125. Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]